Antibacterial Agents TRIZ Cases

Microemulsion formulation reduces withholding periods by maintaining controlled release without high viscosity.

Combined probiotic strains suppress multidrug-resistant bacteria without triggering further antibiotic resistance.

Aliphatic diisocyanate parameter changes eliminate toxic degradation products while semi-crystalline phase transitions provide shear resistance.

Crystalline salt forms of pharmaceutical compounds ensure reliable plasma concentrations by resolving instability issues in amorphous drug materials.

Carbonate compounds disrupt bacterial quorum sensing to prevent oral biofilm formation, overcoming resistance mechanisms in dental plaque.

Modified ClfA protein bioconjugates link saccharide antigens to carrier proteins via glycosylation sites.

Synthesizing antifungal compounds via chiral crystallization to enrich enantiomeric purity and balance potency against selectivity trade-offs.

High-throughput peptide microarray identifies antimicrobial sequences via fluorescence detection on silicon wafers.

Segmented carbon chain complexes disrupt microbial membranes via targeted binding, eliminating toxic side effects while maintaining high antimicrobial efficacy.

Modified benzoxaborole structures target tRNA synthetases to overcome multidrug-resistant bacterial infections.

Diazepane compounds target bromodomain proteins to resolve specificity trade-offs in treating proliferative diseases.

Shared tags on binding agents enable a single anti-tag antibody to target diverse pathogens, reducing production complexity and storage costs.

Optimized inactivated ERAV and ERBV strains reduce respiratory disease incidence while maintaining safety.

Precise genetic manipulation of Yersinia pestis ensures vaccine stability while maintaining broad protection against bubonic and pneumonic plague.

C4BP isoforms lacking beta chains generate tolerogenic dendritic cells to block self-reactive immune functions while preserving infection-clearing capabilities.

Ultrasound catalyzed synthesis of imidazole derivatives overcomes microbial resistance while minimizing environmental harm.

Calcium channel blockers suppress viral replication and modulate immune responses to treat broad-spectrum viral infections while reducing tissue damage.

R-G-Cysteic Acid peptides inhibit integrin-extracellular matrix interactions, reducing neovascularization and eliminating repeated intravitreal injections.

Optimized CDR sequences in IL-1β binding proteins resolve low affinity bottlenecks by delivering high-affinity neutralization for inflammatory disorders.

Segmented cationic peptoid copolymers overcome human cell toxicity while maintaining antimicrobial efficacy against drug-resistant bacteria.

Formula I compounds target PI3K delta and gamma isoforms via local quality design, resolving broad-spectrum side effects.

Polypeptide antigens replace capsular saccharides to provide cross-protection against multiple meningococcal serogroups.

Recombinant viral vectors deliver antimicrobial resistance genes to eukaryotic cells.

A synbiotic formulation combines specific Bifidobacterium strains with prebiotics to regulate gut microecology.

Linking flagellin to O polysaccharide creates a conjugate vaccine that overcomes limited cross-protection in non-typhoidal salmonella strains.

Inhibiting Hsp90 with triazole compounds degrades multiple oncogenic clients simultaneously, overcoming single-target drug resistance in cancer therapy.

Targeting the peptide substrate-binding site instead of the ATP-binding site reduces cardiotoxicity and overcomes drug resistance in cancer treatment.

Nano-emulsions solubilize high flavor oil loads without ethanol, preventing tissue irritation and flammability risks.

Glycerol ester composition prevents pathogenic bacteria from adhering to the intestinal lumen, preserving nutrient absorption and reducing inflammation.

Crystalline acid addition salts of cephalosporin derivative IA improve pharmaceutical purity and storage stability.

Modifying diazabicyclooctane substituents creates broad-spectrum inhibitors that neutralize resistant enzymes like KPC-2 and ESBL.

Hydrophilic components swell the antimicrobial silicone matrix to control silver ion release, resolving insufficient infection control in wound dressings.

Partially deacetylated PNAG vaccine resolves the contradiction between infection risk and immunity induction by isolating immunogenic surface antigens.

Conserved Escherichia coli antigens elicit robust immune responses, addressing broad-spectrum protection limits of current vaccines.

Pyrrolidine sulfonamide compounds block TRPV4 channels, preventing Ca2+ influx that causes pulmonary edema and inflammation.

Trigonelline derivatizes active pharmaceutical ingredients to enhance aqueous solubility across a wide pH range.

Removing cross-reactive antibodies via capsular polysaccharide adsorption improves antigen quantitation accuracy for Streptococcus pneumoniae serotypes.

Benzalkonium chloride prevents SkQ1 from irreversibly adsorbing onto vial walls, maintaining consistent antioxidant concentrations in ophthalmic formulations.

Coexpressing IgA chains and J-chain proteins in CHO cells to resolve low dimeric yield and enhance antigen-binding activity.

Rv1753c antigen targets latent infection to bypass antibiotic resistance and monitoring issues.

Oligo(carbamoylated guanidine) compounds dissipate proton motive force to overcome drug resistance in dormant Mycobacterium tuberculosis cells.

Hydrophilic linkers mediate dehydrogenation reactions to resolve poor mechanical strength and biostability in in situ forming hydrogels.

Uncoated platinum nanoparticles deliver sustained antibacterial activity while preventing discoloration from water or hydrogen sulfide exposure.

Thymoquinone treats drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa infections by overcoming standard antimicrobial susceptibility limits.

Aralkyl benzyl ethers overcome resistant fungal strains by inhibiting sterol biosynthesis.

Macrocyclic indole compounds selectively bind Mcl-1 to induce apoptosis, overcoming chemotherapy resistance driven by anti-apoptotic protein overexpression.